Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 19, Number 8—August 2013

Research

Accuracy of Diagnostic Methods and Surveillance Sensitivity for Human Enterovirus, South Korea, 1999–2011

Ji-Yeon Hyeon, Seoyeon Hwang, Hyejin Kim, Jaehyoung Song, Jeongbae Ahn, Byunghak Kang, Kisoon Kim, Wooyoung Choi, Jae Keun Chung, Cheon-Hyun Kim, Kyungsoon Cho, Youngmee Jee, Jonghyun Kim, Kisang Kim, Sun-Hee Kim, Min-Ji Kim, and Doo-Sung CheonComments to Author 
Author affiliations: Korea Center for Disease Control and Prevention, Cheongwon-gun, Chungcheongbuk-do, South Korea (J.-Y. Hyeon, S. Hwang, H. Kim, J. Song, J. Ahn, B. Kang, Kisoon Kim, W. Choi, Kisang Kim, D.-S. Cheon); Public Health and Environment Institute of Gwangju, Gwangju, South Korea (J.K. Chung, S.-H. Kim, M.-J. Kim); Public Health and Environment Institute of Jeollabukdo, Imsil-gun, Jeollabukdo, South Korea (C.-H. Kim); Public Health and Environment Institute of Busan, Busan, South Korea (K. Cho); World Health Organization, Western Pacific Region, Manila, Philippines (Y. Jee); Catholic University College of Medicine, Suwon, Kyeonggido, South Korea (J. Kim)

Main Article

Table 3

Five most frequent human enterovirus genotype rankings during the epidemic seasons in South Korea, by year, 1999–2011*

Year Genotype, no. (%)
Rank 1 Rank 2 Rank 3 Rank 4 Rank 5
Phase 1†





1999, n = 85 CB2, 21 (24.7) E6, 15 (17.7) CB3, 10 (11.7) E11, 8 (9.4) E30, (8 (9.4)
2000, n = 30 EV71, 12 (40) Polio Sabin strain, 9 (30) CB2, 2 (2.7) E6, 2 (2.7) E11, 2 (2.7)
2001, n = 26 CB5, 12 (46.2) CB3, 4 (15.4) Polio Sabin strain, 3 (11.6) CB2, 3 (11.6) CB1, 3 (11.6)
2002, n = 272 E13, 70 (25.7) E9, 59 (21.7) E6, 53 (19.5) E7, 24 (8.8) CB3, 17 (6.3)
2003, n = 54 CB4, 16 (19.5) E6, 10 (12.2) E30, 7 (8.5) CB1, 7 (8.5) Polio Sabin strain, 5 (6.1)
2004, n = 29 Polio Sabin strain, 7 (24.1) E30, 6 (20.7) CB2, 5 (17.3) CB1, 4 (13.8) E6, 3 (10.3)
Phase 2‡
2005, n = 369 CB5, 159 (43.1) E18, 127 (34.4) CB3, 47 (12.7) E9, 25 (6.8) CB1, 7 (1.9)
2006, n = 238 E25, 56 (23.5) E30, 48 (20.2) E5, 28 (11.8) CA16, 20 (8.4) CB4, 18 (7.6)
2007, n = 180 CB2, 62 (34.4) CA9, 28 (15.6) EV71, 21 (11.7) E16, 14 (7.8) CA10, 10 (5.6)
Phase 3§
2008, n = 626 E30, 299 (47.8) E6, 170 (27.2) CA10, 33 (5.3) CB3, 29 (4.6) CB1, 27 (4.5)
2009, n = 288 EV71, 127 (44.1) CB1, 70 (24.3) CA2, 23 (8.0) CA5, 20 (6.9) CA14, 17 (5.9)
2010, n = 402 EV71, 190 (47.3) CA6, 65 (16.2) CB5, 32 (8.0) CA9, 28 (7.0) CA10, 19 (4.7)
2011, n = 529 EV71, 118 (22.3) CA16, 109 (20.6) CB5, 72 (13.6) CB2, 70 (13.2) E18, 42 (7.9)
Total, 1999–2011, 
n = 3,128 EV71, 476 (14.9) E30, 390 (12.5) CB5, 290 (9.3) E6, 261 (8.4) CB2, 186 (6.0)

*CB, coxsackievirus B; E, echovirus; EV, enterovirus; CA, coxsackievirus A.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO